Evidence map›Paper›PMID 39793550›Full record

ReviewJCO oncology practice2025

Financial Toxicity in Older Adults With Cancer and Their Caregivers.

Sindhuja Kadambi, Ying Wang, Anna Job, Leen Khankan, Tristan Yu, Arpan Patel, Ryan Nipp, Kah Poh Loh

Abstract readReview
In one paragraph

Review in JCO oncology practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. The influence of family resilience and benefit finding on the financial toxicity of primary caregivers of patients with advanced cancer: a cross-sectional study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  3. Review
  4. Article
  5. The impact of social determinants on care for veterans with cancer: a qualitative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  6. Frailty and [Theranostics · 2026
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sindhuja KadambiDivision of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
Ying WangDepartment of Public Health Sciences, University of Rochester Medical Center, Rochester, NY.
Anna JobUniversity of Rochester, Rochester, NY.ORCID 0009-0003-3331-4444
Leen KhankanUniversity of Rochester, Rochester, NY.
Tristan YuUniversity of Rochester, Rochester, NY.
Arpan PatelDivision of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.ORCID 0000-0003-2758-1274
Ryan NippSection of Hematology and Oncology, Department of Medicine, University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, OK.ORCID 0000-0002-4577-3248
Kah Poh LohDivision of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.ORCID 0000-0002-6978-0418

Funding

URCC NCORP Research BaseUG1CA189961 · NCI · UNIVERSITY OF ROCHESTER · PI Michelle C Janelsins, KAREN M. MUSTIAN · 2014 to 2026
$67.7M
Clinical and Translational Cancer Control Research Training ProgramT32CA102618 · NCI · UNIVERSITY OF ROCHESTER · PI Michelle C Janelsins, Gary R Morrow · 2019 to 2026
$2.7M
A novel mobile health exercise intervention for older patients with myeloid neoplasmsR00CA237744 · NCI · UNIVERSITY OF ROCHESTER · PI LOH, KAH POH · 2021 to 2023
$747k
Epigenetic markers, functional status, and exercise in older adults with myeloid neoplasmsR03AG073985 · NIA · UNIVERSITY OF ROCHESTER · PI LOH, KAH POH · 2022 to 2023
$308k
NCI NIH HHS R00 CA237744NCI NIH HHS T32 CA102618NCI NIH HHS UG1 CA189961NIA NIH HHS R03 AG073985
6 · The paper itself

Abstract

With advances in cancer treatment, long-term survival rates have improved in recent decades, resulting in extended life expectancies for many patients. This progress brings substantial challenges, however, particularly in terms of the costs associated with cancer care. The financial burden, often considerable, poses difficulties for older adults with cancer and their caregivers. Financial toxicity refers to the unintended financial consequences and distress that patients and families incur from cancer and its treatment. The prevalence of financial toxicity varies (some estimates with over half experiencing this challenge), and certain subgroups (eg, race other than White and those with lack of social support) are at greater risk. Although studies focusing on older adults are limited, existing research has shown that financial toxicity is associated with adverse outcomes, including delayed care, poorer physical, social, and psychological well-being, and lower overall quality of life. Moreover, financial toxicity may result in negative caregiver health outcomes, which can in turn affect patient outcomes. These negative caregiver effects may persist into the bereavement phase. Various methods are available to assess financial toxicity, and they consist of three domains: material, psychological, and behavioral. Available interventions focus on identifying those at risk and providing financial counseling, navigation, and literacy, as well as tangible assistance. Although the impact of financial toxicity is increasingly recognized, studies in older adults and their caregivers are lacking. A better understanding of their needs is important to develop interventions aimed at mitigating financial toxicity in older adults with cancer and their caregivers.

Indexed as

CaregiversCost of IllnessNeoplasmsAgedHumansQuality of Life

Identifiers

PMID39793550
PMCPMC11731888

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.